Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 315

  • Unknown sort schema '{last_sort_schema}' ignored
  • The following term was not found in PubMed: P%5BAuthor%5D.

Nivolumab to control molecular response in chronic myeloid leukemia.

Rousselot P, Renard P, de Buyer A, Finet A, Spentchian M, Saiag P.

Leuk Res. 2018 Jul 26;72:5-6. doi: 10.1016/j.leukres.2018.07.011. [Epub ahead of print] No abstract available.


Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients.

Roger A, Finet A, Boru B, Beauchet A, Mazeron JJ, Otzmeguine Y, Blom A, Longvert C, de Maleissye MF, Fort M, Funck-Brentano E, Saiag P.

Oncoimmunology. 2018 Mar 13;7(7):e1442166. doi: 10.1080/2162402X.2018.1442166. eCollection 2018.


Molecular recognition of wood polyphenols by phase II detoxification enzymes of the white rot Trametes versicolor.

Schwartz M, Perrot T, Aubert E, Dumarçay S, Favier F, Gérardin P, Morel-Rouhier M, Mulliert G, Saiag F, Didierjean C, Gelhaye E.

Sci Rep. 2018 May 31;8(1):8472. doi: 10.1038/s41598-018-26601-3.


Truncating mutations of TP53AIP1 gene predispose to cutaneous melanoma.

Benfodda M, Gazal S, Descamps V, Basset-Seguin N, Deschamps L, Thomas L, Lebbe C, Saiag P, Zanetti R, Sacchetto L, Chiorino G, Scatolini M, Grandchamp B, Bensussan A, Soufir N.

Genes Chromosomes Cancer. 2018 Jun;57(6):294-303. doi: 10.1002/gcc.22528. Epub 2018 Feb 21.


[A rare complication of a permanent tattoo].

Bounniyt H, Guth-Muller S, Zimmermann U, Blom A, Saiag P.

Presse Med. 2018 Jan;47(1):94-95. doi: 10.1016/j.lpm.2017.10.013. Epub 2017 Dec 20. French. No abstract available.


On/off dropped head syndrome: A severe adverse event after prolonged treatment with MEK inhibitor.

Longvert C, Maisonobe T, Saiag P, Auré K.

Eur J Cancer. 2018 Mar;91:174-176. doi: 10.1016/j.ejca.2017.11.027. Epub 2017 Dec 15. No abstract available.


Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma.

Schadendorf D, Nghiem P, Bhatia S, Hauschild A, Saiag P, Mahnke L, Hariharan S, Kaufman HL.

Oncoimmunology. 2017 Aug 31;6(10):e1338237. doi: 10.1080/2162402X.2017.1338237. eCollection 2017. Review.


European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC.

Nast A, Spuls PI, van der Kraaij G, Gisondi P, Paul C, Ormerod AD, Saiag P, Smith CH, Dauden E, de Jong EM, Feist E, Jobling R, Maccarone M, Mrowietz U, Papp KA, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Dressler C.

J Eur Acad Dermatol Venereol. 2017 Dec;31(12):1951-1963. doi: 10.1111/jdv.14454. Epub 2017 Sep 11. No abstract available.


Primary medical therapy for BRAFV600E-mutant melanoma brain metastases-is this good enough? - Authors' reply.

Davies MA, Saiag P, Long GV.

Lancet Oncol. 2017 Sep;18(9):e509. doi: 10.1016/S1470-2045(17)30640-X. No abstract available.


STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.

Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C; GCC (French Group of Skin Cancer).

J Invest Dermatol. 2018 Jan;138(1):58-67. doi: 10.1016/j.jid.2017.07.839. Epub 2017 Aug 24.


Variation of mutant allele frequency in NRAS Q61 mutated melanomas.

Hélias-Rodzewicz Z, Funck-Brentano E, Terrones N, Beauchet A, Zimmermann U, Marin C, Saiag P, Emile JF.

BMC Dermatol. 2017 Jul 1;17(1):9. doi: 10.1186/s12895-017-0061-x.


Reply to "Clinical and therapeutic implications of BRAF mutation heterogeneity in metastatic melanoma" by Mesbah Ardakani et al.

Boespflug A, Funck-Brentano E, Hélias-Rodzewicz Z, Maucort-Boulch D, Beauchet A, Bringuier PP, Dumontet C, Emile JF, Saiag P, Dalle S.

Pigment Cell Melanoma Res. 2017 Sep;30(5):498-500. doi: 10.1111/pcmr.12606. Epub 2017 Jul 23. No abstract available.


Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV.

Lancet Oncol. 2017 Jul;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1. Epub 2017 Jun 4.


Sensitivity and specificity of BP180 NC16A enzyme-linked immunosorbent assay for the diagnosis of pemphigoid gestationis.

Al Saif F, Jouen F, Hebert V, Chiavelli H, Darwish B, Duvert-Lehembre S, Joly P; French Study Group on Autoimmune Bullous Skin Diseases.

J Am Acad Dermatol. 2017 Mar;76(3):560-562. doi: 10.1016/j.jaad.2016.09.030. No abstract available.


Quality of life, psychological characteristics, and adjustment in parents of children with Attention-Deficit/Hyperactivity Disorder.

Cappe E, Bolduc M, Rougé MC, Saiag MC, Delorme R.

Qual Life Res. 2017 May;26(5):1283-1294. doi: 10.1007/s11136-016-1446-8. Epub 2016 Oct 31.


Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).

Saiag P, Gutzmer R, Ascierto PA, Maio M, Grob JJ, Murawa P, Dreno B, Ross M, Weber J, Hauschild A, Rutkowski P, Testori A, Levchenko E, Enk A, Misery L, Vanden Abeele C, Vojtek I, Peeters O, Brichard VG, Therasse P.

Ann Oncol. 2016 Oct;27(10):1947-53. doi: 10.1093/annonc/mdw291. Epub 2016 Aug 8.


Pembrolizumab-Induced Demyelinating Polyradiculoneuropathy.

de Maleissye MF, Nicolas G, Saiag P.

N Engl J Med. 2016 Jul 21;375(3):296-7. doi: 10.1056/NEJMc1515584. No abstract available.


Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2016.

Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Bastholt L, Grob JJ, Malvehy J, Newton-Bishop J, Stratigos AJ, Pehamberger H, Eggermont AM; European Dermatology Forum (EDF); European Association of Dermato-Oncology (EADO); European Organisation for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2016 Aug;63:201-17. doi: 10.1016/j.ejca.2016.05.005. Epub 2016 Jun 29.


[Items that justify a day-care hospital stay for the management of skin cancer. Guidelines from the Oncodermatology Group of the Société Française de Dermatologie].

Mortier L, Saiag P, Thomas L, Lebbe C, Maubec E, Meyer N, Jouary T, Dalac S, Lesimple T, Dreno B, Richard MA, Leccia MT; groupe de cancérologie de la Société française de dermatologie.

Ann Dermatol Venereol. 2016 Aug-Sep;143(8-9):559-61. doi: 10.1016/j.annder.2016.02.031. Epub 2016 Jun 27. French. No abstract available.


First-in-human phase I study of the DNA-repair inhibitor DT01 in combination with radiotherapy in patients with skin metastases from melanoma.

Le Tourneau C, Dreno B, Kirova Y, Grob JJ, Jouary T, Dutriaux C, Thomas L, Lebbé C, Mortier L, Saiag P, Avril MF, Maubec E, Joly P, Bey P, Cosset JM, Sun JS, Asselain B, Devun F, Marty ME, Dutreix M.

Br J Cancer. 2016 May 24;114(11):1199-205. doi: 10.1038/bjc.2016.120. Epub 2016 May 3.

Supplemental Content

Loading ...
Support Center